Dyadic International (DYAI) Share-based Compensation (2018 - 2026)
Dyadic International (DYAI) posted Share-based Compensation of $10266.0 for Q1 2026, down 94.66% sequentially from $192339.0 in Q4 2025, and down 95.44% YoY from $225030.0 in Q1 2025.
Dyadic International (DYAI) Share-based Compensation (2018 - 2026) Analysis & Trends
Dyadic International has reported Share-based Compensation for 9 years, with the latest figure at $10266.0 in Q1 2026.
- Quarterly Share-based Compensation fell 95.44% year-over-year to $10266.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $715419.0 (down 31.53% YoY) and the FY2025 annual result came in at $930183.0, down 17.41% from the prior year.
- Share-based Compensation fell to $10266.0 in Q1 2026 per DYAI's latest filing, from $192339.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $1.9 million in Q4 2022 and troughed at -$789279.0 in Q4 2023.
- A 5-year average of $324756.8 and a median of $297603.0 in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation soared 310.91% in 2022, then plunged 141.78% in 2023.
- Over 5 years, Share-based Compensation stood at $1.9 million in 2022, then slumped by 141.78% to -$789279.0 in 2023, then soared by 134.82% to $274808.0 in 2024, then plunged by 30.01% to $192339.0 in 2025, then tumbled by 94.66% to $10266.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $10266.0, $192339.0, and $172352.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Dyadic International | 20.18 Mn | 20.18 Mn | - | 139,299.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10,266.00 |
| Mar 31, 2026 | 10,266.00 |
| Dec 31, 2025 | 192,339.00 |
| Dec 31, 2025 | 192,339.00 |
| Sep 30, 2025 | 172,352.00 |
| Sep 30, 2025 | 172,352.00 |
| Jun 30, 2025 | 340,462.00 |
| Jun 30, 2025 | 340,462.00 |
| Mar 31, 2025 | 225,030.00 |
| Mar 31, 2025 | 225,030.00 |
| Dec 31, 2024 | 274,808.00 |
| Dec 31, 2024 | 274,808.00 |
| Sep 30, 2024 | 247,390.00 |
| Sep 30, 2024 | 247,390.00 |
| Jun 30, 2024 | 297,603.00 |
| Jun 30, 2024 | 297,603.00 |
| Mar 31, 2024 | 306,478.00 |
| Mar 31, 2024 | 306,478.00 |
| Dec 31, 2023 | -789,279.00 |
| Dec 31, 2023 | -789,279.00 |